LEARN MORE FROM THE LINKS BELOW:
Clinical Study 1: ENSPRYNG Alone
Clinical Study 2: ENSPRYNG + IST
Possible Side Effects
How ENSPRYNG Works

ENSPRYNG is the first approved self-injectable treatment for NMOSD

  • It is intended for self-administration under the guidance of a healthcare provider. After proper training, an adult patient or caregiver may inject ENSPRYNG
  • It is a subcutaneous injection given under the skin via a prefilled syringe
  • It is appropriate for adults with NMOSD who are AQP4-IgG(+)
  • It is designed to block a protein called interleukin-6 (IL-6) that affects the immune system, and is believed to play a part in NMOSD

ENSPRYNG was examined for safety and effectiveness in 2 clinical studies. ENSPRYNG met the main goal of both studies by reducing the risk of relapse and resulted in more patients who were relapse-free at 2 years.

Study 1: ENSPRYNG vs placebo
95 adult patients were included in the study and were randomly chosen to take ENSPRYNG or placebo. Of the 63 patients that took ENSPRYNG, 41 tested AQP4-IgG(+). Of the 32 patients who took placebo, 23 tested AQP4-IgG(+).

 

ENSPRYNG significantly reduced the risk of relapse and more patients were relapse-free on ENSPRYNG vs placebo in the AQP4-IgG(+) patient group

ENSPRYNG significantly reduced the risk of relapse by

74% vs placebo

More patients were relapse-free at 2 years with ENSPRYNG vs placebo

77% of AQP4-IgG(+) patients on ENSPRYNG and 41% of AQP4-IgG(+) patients on placebo were relapse-free at 2 years.

Talk with your healthcare provider to see if starting ENSPRYNG is right for you.

Study 2: ENSPRYNG plus IST vs placebo plus IST
76 adult patients were included in the study and were randomly chosen to take ENSPRYNG or placebo. Of the 37 that took ENSPRYNG, 26 tested AQP4-IgG(+). Of the 39 patients who took placebo, 26 tested AQP4-IgG(+).

 

ENSPRYNG significantly reduced the risk of relapse and more patients were relapse-free on ENSPRYNG plus IST vs placebo plus IST in the AQP4-IgG(+) patient group

ENSPRYNG plus IST significantly reduced the risk of relapse by

78% vs placebo

More patients were relapse-free at 2 years with ENSPRYNG plus IST vs placebo plus IST

91% of AQP4-IgG(+) patients on ENSPRYNG plus IST and 57% of AQP4-IgG(+) patients on placebo plus IST were relapse-free at 2 years.

Discuss the ENSPRYNG study results with your healthcare provider to see what they could mean for you.

Select side effects with ENSPRYNG

Infections

ENSPRYNG can increase your risk of serious infections some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection or call them right away if you think you have signs of an infection, with or without a fever, such as:

  • Chills, feeling tired, muscle aches, cough that will not go away or a sore throat
  • Skin redness, swelling, tenderness, pain or sores on your body
  • Diarrhea, belly pain, or feeling sick
  • Burning when you urinate or urinating more often than usual

Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG. For additional safety information, refer to the ENSPRYNG Medication Guide.

You should talk to your healthcare provider right away if you experience any side effects or changes in your health while taking ENSPRYNG.

How ENSPRYNG is thought to work

  • ENSPRYNG is the first approved treatment in NMOSD that is engineered to block interleukin-6 (IL-6)
  • IL-6 is a protein in our bodies made by many immune cells that may play a role in the inflammation that occurs in people with NMOSD

Without ENSPRYNG:
IL-6 connects to the cell surface and activates the cell.

With ENSPRYNG:
ENSPRYNG blocks IL-6 from connecting to the cell surface and prevents the activation of the cell.

Sign up to learn more about ENSPRYNG and how it works with NMOSD.

FIND OUT ABOUT THE ENSPRYNG DOSING SCHEDULE

HOW TO TAKE ENSPRYNG